К. К. Лактионов

机构：Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, Kementerian Kesehatan Republik Indonesia · ORCID：0000-0003-4469-502X

发表论文 288 篇 · 总被引 13182 次 · h-index 29

代表论文

• Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB–IIIA non-small-cell lung cancer (2025 · Nature Medicine · 被引 54)
• Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study (2025 · Journal of Clinical Oncology · 被引 50)
• Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study (2024 · Journal of Thoracic Oncology · 被引 9)
• Немелкоклеточный рак легкого (2024 · Malignant tumours · 被引 6)
• Немелкоклеточный рак легкого (2025 · Malignant tumours · 被引 2)
• A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC (2025 · Future Oncology · 被引 2)